Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma.
| Website | https://thirdharmonicbio.com/ |
| Revenue | $46.6 million |
| Employees | 9 (9 on RocketReach) |
| Founded | 2019 |
| Address | 1700 Montgomery St Suite 210, San Francisco, California 94111, US |
| Phone | +1 860-908-6924 |
| Industry | Biotechnology Research |
| Keywords | Clinical Stage Biopharmaceutical, Biopharmaceutical Development, Drug Development, Targeted Therapy, Precision Medicine, Innovative Therapeutics, New Drug Development, Inflammatory Bowel Disease Treatment, Clinical Trials |
| Competitors | Roche, Novartis, AbbVie, Sanofi, Bristol Myers Squibb, Amgen, Regeneron, Gilead Sciences, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +36 more (view full list) |
Looking for a particular Third Harmonic Bio employee's phone or email?
The Third Harmonic Bio annual revenue was $46.6 million in 2026.
Chris Murphy is the Chief Financial and Business Officer of Third Harmonic Bio.
9 people are employed at Third Harmonic Bio.
Third Harmonic Bio is based in San Francisco, California.